CAR-iNKT for AML / Gilead, Appia Bio - LARVOL DELTA

Kite and Appia Bio Announce Collaboration to Research and Develop Allogeneic Cell Therapies for Cancer (Businesswire) - "Kite...announced a collaboration and license agreement to research and develop HSC-derived cell therapies directed toward hematological malignancies. Under the partnership, Kite and Appia Bio will develop chimeric antigen receptor (CAR)-engineered invariant natural killer T (CAR-iNKT) cells using Appia Bio’s ACUA technology platform for allogeneic cell therapy....Under the terms of the agreement, Appia Bio will be responsible for preclinical and early clinical research of two HSC-derived CAR-iNKT product candidates engineered with CARs provided by Kite."

Licensing / partnership • Oncology